Northwestern University Human Resources
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1851-01-28
- Employees
- 5K
- Market Cap
- -
Bevacizumab in Treating Patients With Recurrent or Progressive Glioma
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- Biological: bevacizumab
- First Posted Date
- 2006-06-15
- Last Posted Date
- 2020-02-07
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 55
- Registration Number
- NCT00337207
- Locations
- 🇺🇸
Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States
🇺🇸Hematology-Oncology Associates of Illinois, Chicago, Illinois, United States
Radiation Therapy, Chemotherapy, and Bevacizumab in Treating Patients With Recurrent, Unresectable or Stage III or Stage IV Non-Small Cell Lung Cancer
- Conditions
- Lung Cancer
- First Posted Date
- 2006-06-08
- Last Posted Date
- 2012-07-10
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 32
- Registration Number
- NCT00334763
- Locations
- 🇺🇸
Lurleen Wallace Comprehensive Cancer at University of Alabama - Birmingham, Birmingham, Alabama, United States
🇺🇸Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States
🇺🇸Evanston Northwestern Healthcare - Evanston Hospital, Evanston, Illinois, United States
Abraxane and Lapatinib in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2006-05-31
- Last Posted Date
- 2020-03-06
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 30
- Registration Number
- NCT00331630
- Locations
- 🇺🇸
Northwestern University, Northwestern Medical Faculty Foundation, Chicago, Illinois, United States
🇺🇸Hematology-Oncology Associates of Illinois, Chicago, Illinois, United States
🇺🇸Midwest Center for Hematology/Oncology, Joliet, Illinois, United States
Lapatinib and Doxorubicin Hydrochloride Liposome in Treating Patients With Metastatic Breast Cancer
- First Posted Date
- 2006-04-21
- Last Posted Date
- 2013-11-08
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 23
- Registration Number
- NCT00316875
- Locations
- 🇺🇸
Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States
Translating the DPP Into the Community
- Conditions
- Prediabetic StateOverweightObesity
- Interventions
- Behavioral: Brief Counseling for pre-diabetes aloneBehavioral: Brief counseling plus group diabetes prevention in community
- First Posted Date
- 2006-03-13
- Last Posted Date
- 2017-07-18
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 92
- Registration Number
- NCT00302042
- Locations
- 🇺🇸
Indiana University Diabetes Prevention and Control Center, Indianapolis, Indiana, United States
Feasibility of a Partnered Approach to Prevent Diabetes
- Conditions
- ObesityPre-diabetic StateOverweight
- Interventions
- Behavioral: Clinical referral to group diabetes prevention lifestyleBehavioral: Clinical referral to diabetes prevention lifestyle
- First Posted Date
- 2006-03-13
- Last Posted Date
- 2016-12-01
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 72
- Registration Number
- NCT00302055
- Locations
- 🇺🇸
IU Medical Group Banta Road Clinic, Indianapolis, Indiana, United States
🇺🇸IU Medical Group Westside Clinic, Indianapolis, Indiana, United States
Phase I/II Study of High-Dose Calcitriol Plus Temodar for Patients With Metastatic Melanoma
- Conditions
- Metastatic Melanoma
- Interventions
- Dietary Supplement: Calcitriol
- First Posted Date
- 2006-03-10
- Last Posted Date
- 2019-06-04
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 20
- Registration Number
- NCT00301067
- Locations
- 🇺🇸
Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States
D-cycloserine in the Management of Chemotherapy-Induced Peripheral Neuropathic Pain
- Conditions
- NeurotoxicityPainBreast Cancer
- Interventions
- Other: Placebo
- First Posted Date
- 2006-03-10
- Last Posted Date
- 2013-12-02
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 7
- Registration Number
- NCT00301080
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸University of Wisconsin School of Medicine, Madison, Wisconsin, United States
A Phase I/II Trial of VELCADE & Gemcitabine for Patients With Relapsed or Refractory Aggressive B- and T-cell Non-Hodgkin's Lymphoma
- First Posted Date
- 2006-02-13
- Last Posted Date
- 2019-05-28
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 32
- Registration Number
- NCT00290706
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸Veterans Affairs Medical Center - Lakeside Chicago, Chicago, Illinois, United States
🇺🇸University of Chicago Cancer Research Center, Chicago, Illinois, United States
Bevacizumab in Treating Patients With Angiosarcoma
- Conditions
- Sarcoma
- Interventions
- Biological: Bevacizumab
- First Posted Date
- 2006-02-07
- Last Posted Date
- 2018-06-25
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 32
- Registration Number
- NCT00288015
- Locations
- 🇺🇸
Rebecca and John Moores UCSD Cancer Center, La Jolla, California, United States
🇺🇸Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States
🇺🇸Fox Chase Cancer Center CCOP Research Base, Philadelphia, Pennsylvania, United States